Cartesian Therapeutics Reports Presentation Of Data From Its Phase 2b Trial Of Descartes-08 In Patients With Generalized Myasthenia Gravis;

Benzinga · 10/15 11:47
  • The trial achieved its primary endpoint with statistical significance in the pre-specified modified intent-to-treat efficacy population, with 71% (10/14) of patients treated with Descartes-08 observed to have 5-point or greater improvements in MG Composite (MGC) score at Month 3 compared to 25% (3/12) of patients treated with placebo (p=0.018).
Carsten Brunn, Ph.D., President and Chief Executive Officer, said, "We look forward to continuing to collaborate with the FDA to determine next steps for the Descartes-08 program for MG and plan to hold an End-of-Phase 2 meeting by the end of this year."